Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Pharma marketing is constantly changing and #AI is helping to reshape how brands connect with their audiences.
Discover Medico Digital top 5 #AI predictions and learn how harnessing the power of AI can boost your marketing strategy. Read more here.
Luscii provides the tools for patient and professional to keep an eye on the recovery while checking vital signs and symptoms to signal deteriorations and intervene timely in case of need.
Read more here.
Attendees
Sponsors and Exhibitors
Media
Contact us